Sarcopenia in MASLD-Eat to Beat Steatosis, Move to Prove Strength
- PMID: 39796612
- PMCID: PMC11722590
- DOI: 10.3390/nu17010178
Sarcopenia in MASLD-Eat to Beat Steatosis, Move to Prove Strength
Abstract
The connections between sarcopenia and various chronic conditions, including type 2 diabetes (T2DM), metabolic syndrome (MetS), and liver disease have been highlighted recently. There is also a high occurrence of sarcopenia in metabolic dysfunction-associated steatotic liver disease (MASLD) patients, who are often disregarded. Both experimental and clinical findings suggest a complex, bidirectional relationship between MASLD and sarcopenia. While vitamin D, testosterone, and specific drug therapies show promise in mitigating sarcopenia, consensus on effective treatments is lacking. Recent focus on lifestyle interventions emphasizes dietary therapy and exercise for sarcopenic obesity in MASLD. Challenges arise as weight loss, a primary MASLD treatment, may lead to muscle mass reduction. The therapeutic approach to sarcopenia in morbidly obese MASLD patients also includes bariatric surgery (BS). BS induces weight loss and stabilizes metabolic imbalances, but its impact on sarcopenia is nuanced, underscoring the need for further research. Our aim is to provide a comprehensive review of the interplay between sarcopenia and MASLD and offer insight into the most recent therapeutic challenges and discoveries, as sarcopenia is often overlooked or unrecognized and poses significant challenges for managing these patients.
Keywords: MASLD; metabolic syndrome; sarcopenia; sarcopenic obesity; type 2 diabetes.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?Metabolism. 2024 Aug;157:155937. doi: 10.1016/j.metabol.2024.155937. Epub 2024 May 21. Metabolism. 2024. PMID: 38782182 Review.
-
Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study.BMC Gastroenterol. 2025 Feb 11;25(1):75. doi: 10.1186/s12876-025-03661-0. BMC Gastroenterol. 2025. PMID: 39934679 Free PMC article.
-
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3. Diabetologia. 2024. PMID: 38869512 Free PMC article.
-
Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis.Curr Cardiol Rep. 2025 Jan 18;27(1):28. doi: 10.1007/s11886-024-02185-5. Curr Cardiol Rep. 2025. PMID: 39826021 Free PMC article. Review.
-
Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Nutrients. 2024 Feb 26;16(5):658. doi: 10.3390/nu16050658. Nutrients. 2024. PMID: 38474786 Free PMC article. Review.
Cited by
-
Metabolic Dysfunction-Associated Steatotic Liver Disease Induced by Microplastics: An Endpoint in the Liver-Eye Axis.Int J Mol Sci. 2025 Mar 21;26(7):2837. doi: 10.3390/ijms26072837. Int J Mol Sci. 2025. PMID: 40243419 Free PMC article. Review.
-
The prognostic value of sarcopenia in acute-on-chronic liver failure: a systematic review and meta-analysis.BMC Gastroenterol. 2025 Apr 26;25(1):300. doi: 10.1186/s12876-025-03926-8. BMC Gastroenterol. 2025. PMID: 40287653 Free PMC article.
-
Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study.Int J Mol Sci. 2025 Jun 10;26(12):5561. doi: 10.3390/ijms26125561. Int J Mol Sci. 2025. PMID: 40565024 Free PMC article. Clinical Trial.
References
-
- Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2 (2019). Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31. doi: 10.1093/ageing/afy169. - DOI - PMC - PubMed
-
- Studenski S.A., Peters K.W., Alley D.E., Cawthon P.M., McLean R.R., Harris T.B., Ferrucci L., Guralnik J.M., Fragala M.S., Kenny A.M., et al. The FNIH sarcopenia project: Rationale, study description, conference recommendations, and final estimates. J. Gerontol. A Biol. Sci. Med. Sci. 2014;69:547–558. doi: 10.1093/gerona/glu010. - DOI - PMC - PubMed
-
- Bhasin S., Travison T.G., Manini T.M., Patel S., Pencina K.M., Fielding R.A., Magaziner J.M., Newman A.B., Kiel D.P., Cooper C., et al. Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium. J. Am. Geriatr. Soc. 2020;68:1410–1418. doi: 10.1111/jgs.16372. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources